General MedicationsNASALStandard
SUMATRIPTAN
SUMATRIPTAN
Standard Dose
5MG/SPRAY
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SUMATRIPTAN is listed in Drugs@FDA under application 213650 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient SUMATRIPTAN Form and strength SPRAY;NASAL - 5MG/SPRAY Sponsor PERRIGO UK FINCO Submission history Latest submission status date: 2020-09-21 00:00:00.
Structured Monograph
Clinical summary
Approval overview SUMATRIPTAN is listed in Drugs@FDA under application 213650 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient SUMATRIPTAN Form and strength SPRAY;NASAL - 5MG/SPRAY Sponsor PERRIGO UK FINCO Submission history Latest submission status date: 2020-09-21 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.